rna
interfer
endogen
cellular
process
inhibit
gene
express
mediat
sequencespecif
doublestrand
rna
dsrna
phenomenon
first
observ
petunia
flower
later
report
caenorhabd
elegan
dsrna
bp
length
produc
cleavag
long
rna
duplex
dicer
ribonucleas
iiityp
enzym
produc
small
interf
rna
sirna
duplex
activ
process
degrad
mrna
transcript
contain
target
sequenc
process
driven
sirnaenzym
complex
rnainduc
silenc
complex
risc
result
inhibit
gene
express
interestingli
dsrna
artifici
gener
either
direct
chemic
synthesi
fold
singl
rna
short
dsrna
hairpin
loop
target
specif
mrna
sequenc
induc
degrad
mrna
therefor
rna
interfer
tool
downregul
gene
express
cultur
cell
well
live
organ
two
import
issu
must
consid
applic
sirna
downregul
gene
express
becom
realiti
gener
effect
dsrna
ii
deliveri
dsrna
target
cell
organ
address
first
issu
research
establish
two
strategi
first
one
chemic
synthes
sirna
method
two
singlestrand
complementari
short
rna
oligonucleotid
synthes
two
short
oligonucleotid
anneal
dsrna
test
tube
usual
short
oligonucleotid
nucleotid
design
twonucleotid
overhang
facilit
activ
risc
process
mrna
cleavag
addit
group
group
gener
enhanc
function
sirna
duplex
simpl
quick
applic
chemic
synthesi
strategi
shown
limit
stabil
product
cost
sirna
overcom
limit
chemic
synthesi
sirna
plasmidbas
strategi
develop
strategi
dsrna
bp
hairpin
loop
nine
nucleotid
design
express
plasmid
control
promot
cell
rna
molecul
subject
cleavag
dicer
gener
sirna
sinc
dna
plasmid
easili
econom
produc
escherichia
coli
strategi
wide
adopt
character
gene
function
vitro
therapeut
studi
address
issu
relat
deliveri
sirna
cell
live
organ
research
use
sever
approach
includ
direct
introduct
chemic
synthes
sirna
ii
employ
liposomeconjug
sirna
plasmid
iii
applic
viral
vector
express
dsrna
hairpin
loop
method
advantag
disadvantag
recent
numer
paper
report
sirna
technolog
potent
tool
knockdown
gene
express
therapeut
potenti
treatment
variou
human
diseas
rang
cancer
infecti
diseas
eg
hiv
hepat
review
focu
applic
sirna
technolog
sar
reader
also
refer
anoth
recent
review
subject
genom
sequenc
sarscov
determin
mechan
replic
becam
appar
similar
other
coronaviru
famili
sirna
target
differ
gene
sarscov
use
variou
group
inhibit
viru
gene
express
thereaft
inhibit
replic
viru
see
tabl
initi
report
came
two
group
use
chemic
synthesi
strategi
first
group
show
two
six
chemic
synthes
sirna
base
sarscov
genom
sequenc
result
inhibit
viral
cytopath
effect
cpe
cell
infect
strain
cursori
evalu
cpe
transfect
cell
provid
evid
sirna
might
effect
inhibit
sarscov
replic
second
group
demonstr
three
six
sirna
design
target
replicas
sarscov
moder
effect
wherea
three
less
effect
around
time
zhang
et
al
use
vectorbas
strategi
design
two
differ
sirna
target
sequenc
encod
protein
sarscov
sequenc
chosen
ident
differ
sarscov
strain
author
insert
sirna
sequenc
vector
promot
express
sirna
cell
group
research
first
demonstr
sirna
inhibit
gene
express
viru
replic
vero
cell
infect
sarscov
strain
studi
provid
strong
evid
sirna
target
gene
could
employ
potenti
tool
inhibit
sarscov
replic
even
though
protein
high
mutat
rate
target
mrna
also
report
group
effect
inhibit
sarscov
replic
meanwhil
wang
et
al
adopt
similar
strategi
target
viral
rna
polymeras
gene
sarscov
group
use
commerci
avail
vector
psuperretro
design
six
sirna
research
observ
vero
cell
infect
sarscov
strain
two
six
sirna
dramat
effect
inhibit
viral
replic
effect
target
rna
polymeras
gene
confirm
lu
et
al
meng
et
al
avoid
tediou
work
construct
plasmid
vector
test
effect
target
sequenc
zheng
et
al
chemic
synthes
sirna
duplex
target
region
throughout
entir
sarscov
rna
genom
includ
open
read
frame
sever
key
protein
transfect
sirna
duplex
fetal
rhesu
kidney
cell
prior
infect
viru
evalu
effici
sirna
inhibit
viral
replic
found
four
sirna
duplex
potent
inhibitori
effect
sarscov
infect
replic
evalu
intracellular
viral
genom
copi
number
viral
titer
cell
cultur
medium
use
quantit
revers
transcript
pcr
qrtpcr
cpebas
titrat
respect
studi
prolong
prophylact
effect
sirna
duplex
inhibit
last
least
hour
observ
combin
activ
sirna
duplex
target
differ
region
viral
genom
result
inhibit
vitro
conveni
rapid
gener
chemic
synthes
sirna
duplex
seem
attract
identif
target
follow
studi
zheng
et
al
shi
et
al
synthes
sirna
duplex
show
three
effect
inhibit
express
report
gene
carri
target
sequenc
vero
cell
improv
effect
inhibit
group
adopt
strategi
util
mutat
nucleotid
last
pair
duplex
tt
overhang
found
modif
duplex
increas
inhibitori
effect
sarscov
gene
express
observ
confirm
mismatch
end
antisens
sirna
enhanc
effect
recent
sirna
inhibit
sarscov
gene
express
replic
report
wu
et
al
describ
three
chemic
synthes
sirna
duplex
target
gene
sequenc
zhao
et
al
design
sever
sirna
target
sequenc
encod
n
protein
recent
meng
et
al
identifi
sirna
target
e
rdrp
gene
interestingli
two
group
report
effect
target
leader
sequenc
sarscov
li
et
al
first
identifi
leader
sequenc
mrna
encod
differ
structur
protein
base
find
reason
sirna
target
leader
sequenc
effect
inhibit
viral
replic
cell
cultur
system
sinc
would
target
number
protein
simultan
research
group
provid
evid
sirna
target
leader
sequenc
via
promoterbas
vector
stronger
effect
inhibit
sarscov
replic
sirna
target
gene
later
ni
et
al
select
three
potenti
sirna
sequenc
target
leader
sequenc
demonstr
three
sirna
deliv
vector
dramat
inhibit
sarscov
replic
measur
either
plaqu
format
level
mrna
protein
n
anoth
group
find
signific
inhibitori
effect
chemic
synthes
sirna
duplex
target
leader
sequenc
li
et
al
ni
et
al
separ
demonstr
effect
vectordriven
sirna
target
leader
sequenc
whether
differ
vectordriven
chemic
synthes
sirna
remain
unclear
ration
design
effect
sirna
inhibit
sarscov
replic
remain
difficult
author
select
target
sequenc
mainli
empir
test
select
target
sequenc
usual
specif
featur
previou
report
suggest
eas
select
sirna
target
sequenc
meng
et
al
adopt
cellbas
assay
screen
sirna
block
sarscov
gene
express
assay
involv
two
gene
encod
rdrp
envelop
e
protein
respect
author
verifi
publish
sequenc
valid
two
sirna
site
rdrp
gene
two
site
envelop
e
gene
assay
provid
specif
strategi
select
effect
sirna
sequenc
consid
viru
may
possibl
escap
sirna
target
viral
mutat
et
al
use
combin
sirna
target
differ
sequenc
author
reduc
dosag
singl
sirna
duplex
minim
effect
level
test
synergist
effect
combin
differ
duplex
found
combin
sirna
target
two
differ
site
signific
synergist
effect
inhibit
sarscov
replic
infect
cell
howev
still
unclear
whether
synergist
role
could
overcom
problem
viral
escap
mutat
studi
observ
synergist
effect
combin
sirna
duplex
high
dose
although
may
explain
satur
dosag
effect
current
research
use
chemic
synthesi
vectorbas
approach
gener
sirna
sarscov
chemic
synthesi
approach
rapid
easi
test
rna
stabil
problemat
improv
biostabl
elmen
et
al
use
lock
nucleic
acid
lna
approach
design
sirna
report
braasch
et
al
lna
could
increas
thermal
stabil
sirna
duplex
without
deleteri
effect
function
studi
elmen
et
al
indic
incorpor
lna
significantli
enhanc
sirna
stabil
improv
effici
unmodifi
sirna
sarscov
inhibit
studi
demonstr
modif
sirna
duplex
could
substanti
improv
activ
therefor
approach
may
enhanc
develop
sirna
therapeut
intervent
sarscov
date
studi
inhibit
sarscov
replic
use
sirna
conduct
use
cell
line
vitro
howev
anim
studi
date
li
et
al
report
attempt
use
sirna
inhibit
sarscov
infect
rhesu
macaqu
initi
screen
two
chemic
synthes
sirna
select
sirna
base
previou
work
zheng
et
al
research
treat
anim
two
sirna
duplex
commonli
use
glucos
solut
prior
infect
sarscov
found
monkey
treat
group
show
less
sever
symptom
control
group
report
period
observ
administr
sirna
duplex
treat
monkey
show
averag
bodi
temperatur
control
anim
averag
bodi
temperatur
temperatur
chang
correl
chang
lung
histopatholog
intrigu
observ
three
four
anim
three
sirnatr
group
free
sarscov
oropharyng
swab
specimen
base
measur
sarscov
rna
copi
number
indic
sarscov
particl
releas
anim
lung
dramat
reduc
inject
sirna
duplex
whether
sirna
inhibit
sarscov
replic
block
spread
viru
within
lung
remain
determin
howev
studi
clearli
demonstr
sirna
effect
prophylact
therapeut
advers
effect
anim
studi
reduct
viru
lung
may
dramat
reduc
spread
contact
therebi
effect
approach
reduc
spread
viru
patient
caregiv
target
specif
sirna
import
featur
novel
technolog
therapeut
develop
highli
specif
sirna
select
screen
avoid
potenti
offtarget
side
effect
howev
high
specif
also
problem
sinc
singl
nucleotid
chang
diminish
effect
design
sirna
sinc
mutat
sarscov
genom
occur
may
result
viral
escap
sirna
target
et
al
use
combin
differ
sirna
target
differ
sequenc
benefici
effect
sinc
appear
combin
differ
sirna
synergist
effect
inhibit
sarscov
replic
base
data
appear
best
approach
would
use
combin
sirna
maxim
benefit
therefor
suggest
highli
effect
sirna
combin
use
one
possibl
advers
effect
vivo
applic
sirna
may
trigger
host
immun
respons
induct
interferon
howev
sinc
sirna
show
advers
effect
possibl
conduct
screen
sirna
sequenc
anim
undertak
clinic
studi
anoth
potenti
problem
applic
technolog
vivo
sirna
overexpress
may
interfer
endogen
microrna
process
problem
avoid
lower
deliveri
dose
sirna
express
studi
refer
review
demonstr
potent
inhibitori
effect
sirna
chemic
synthes
vector
base
replic
sarscov
cultur
cell
anim
howev
clinic
applic
prophylact
therapeut
context
critic
improv
effici
sirna
deliveri
specif
human
organ
gene
therapi
field
sirna
target
sarscov
hamper
barrier
deliveri
work
done
rhesu
macaqu
li
et
al
adopt
common
glucos
solut
deliv
chemic
synthes
sirna
airway
anim
although
experiment
result
demonstr
dramat
chang
sarscov
replic
remain
unclear
much
sirna
duplex
success
deliv
airway
epitheli
cell
anim
long
vivo
transfect
sirna
duplex
maintain
cell
clearli
area
addit
work
need
howev
confid
recent
work
gene
target
vaccin
formul
hurdl
insurmount
approach
gene
deliveri
airway
greatli
improv
past
decad
especi
use
viral
vector
helperdepend
adenovir
vector
hdad
transduc
almost
airway
epitheli
cell
mice
lesser
degre
rabbit
deliveri
sirna
viral
vector
effect
prophylact
use
sinc
express
sirna
viral
vector
expect
last
much
longer
durat
chemic
synthes
sirna
transfect
cell
although
viral
vector
use
deliv
sirna
sarscov
potenti
advers
effect
inflamm
consid
fact
sirna
use
downregul
express
proinflammatori
cytokin
exampl
cao
et
al
shown
interleukin
il
express
downregul
hdad
express
sirna
target
mrna
airway
epitheli
cell
concern
host
immun
respons
hdad
may
address
use
antiinflammatori
drug
addit
adenoassoci
viral
vector
caus
host
immun
respons
shown
highli
effici
express
sirna
mous
liver
may
adapt
airway
sirna
deliveri
well
therefor
viral
deliveri
approach
may
use
translat
rnai
technolog
clinic
applic
date
studi
perform
compar
effici
sirna
deliveri
vitro
vivo
anim
studi
help
screen
sirna
therapeut
potenti
ration
design
sirna
treatment
sar
also
learn
experi
applic
sirna
diseas
regard
schiffel
storm
report
system
name
develop
system
deliveri
therapeut
sirna
site
patholog
angiogenesi
addit
dykxhoorn
leiberman
recent
comment
differ
approach
intraven
deliveri
sirna
clinic
applic
improv
sirna
design
deliveri
method
rna
interfer
offer
anoth
major
weapon
combat
danger
infect
virus
sarscov
review
summar
applic
sirna
prevent
treatment
sar
although
still
number
problem
need
overcom
technolog
adopt
clinic
applic
believ
progress
sirna
methodolog
help
us
develop
effect
drug
conquer
danger
infecti
diseas
